Stereotaxis said that the prospective multi-center clinical effort, entitled: ‘Study to Obliterate Persistent Ventricular Tachycardia’ (STOP-VT), will be conducted at The Hospital of University of Pennsylvania, Methodist Hospital (Indianapolis), Na Holmoce Hospital (Prague), Loyola University Medical Center (Chicago), and Herzentrum Leipzig GmbH (Germany).

During the upcoming 31st Annual Heart Rhythm Society Scientific Sessions in Denver, CO, additional VT outcome data will be presented by established Stereotaxis users. Hiroshi Nakagawa, co-director of the Heart Rhythm Institute at the University of Oklahoma Health Sciences Center and one of the experts on contact force and lesion formation, will present a paper entitled, ‘Substrate Ablation of Scar Ventricular Tachycardia Using Magnetic Catheter Maneuvering System.’

In addition to the VT data, several Stereotaxis users from around the world will present clinical results related to atrial fibrillation (AF), pediatric and congenital arrhythmia, supraventricular tachycardia (SVT), atrial flutter, and use with implantable devices through a series of presentations and posters.

Michael Kaminski, president and chief executive officer of Stereotaxis, said: “Based upon our excellent clinical results, we believe that treatment with magnetically-enabled radiofrequency catheters can effectively terminate a vast majority of documented ventricular tachycardias in patients who had suffered a previous heart attack. This global initiative further exemplifies our commitment to developing long-term solutions for our EP customers.”

John Miller, professor of Medicine at Krannert Institute of Cardiology, Indiana University School of Medicine, said: “Ablation of ventricular tachycardia is an excellent application for Stereotaxis magnetic navigation. Our experience has been that the precise intricate mapping and enhanced safety of magnetic navigation allows us to perform successful ablation of complex arrhythmias without the pitfalls associated with manual techniques.”